Masitinib cas: 790299-79-5

CAS NO: 790299-79-5
Chemical Information:

Chemical Name: Masitinib
Molecular Formula: C28H30N6OS
Formula Weight: 498.6 g/mol
CAS Number: 790299-79-5
Description Review
Description
Masitinib is a potent inhibitor of the tyrosine kinase receptor, which has garnered significant attention in the medical and pharmaceutical fields. As a multi-targeted protein tyrosine kinase inhibitor, it has shown potential in various therapeutic applications, making it a subject of interest for researchers and clinicians alike.



Chemical Information:

Chemical Name: Masitinib
Molecular Formula: C28H30N6OS
Formula Weight: 498.6 g/mol
CAS Number: 790299-79-5

Top Ten Keywords from Google:
Masitinib
Masitinib for ALS
Masitinib ALS
Masitinib Multiple Sclerosis
Masitinib FDA Approval
Masitinib Mechanism of Action
Masitinib Dog
Masitinib for Dogs
Masitinib Dogs
Masitinib Clinical Trials

Synonyms: AB-1010, Masican, Masiviera
Competitive Products:
While Masitinib stands out in its category, there are other tyrosine kinase inhibitors in the market that serve as its competitors. Some of these include Imatinib, Dasatinib, and Nilotinib. Each of these drugs has its unique properties and applications, but Masitinib's multi-targeted approach gives it an edge in certain therapeutic areas.

Health Benefits:
Masitinib has shown promise in treating various conditions. Its primary benefit lies in its ability to inhibit specific enzymes, potentially slowing the progression of certain diseases. It has been researched for its potential in treating conditions like ALS, multiple sclerosis, and certain types of cancers.

Potential Effects:
The drug's potential effects include slowing disease progression, reducing inflammation, and inhibiting the growth of cancer cells. Its multi-targeted approach means it can be effective in treating a range of conditions.

Product Mechanism:
Masitinib works by targeting and inhibiting specific tyrosine kinases, enzymes responsible for activating many proteins by signal transduction cascades. By inhibiting these enzymes, Masitinib can interfere with the growth and survival of cancer cells.

Safety:
Like all drugs, the safety of Masitinib is of paramount importance. Clinical trials have been conducted to ensure its safety, and while it has been deemed safe for use under specific conditions, it's essential to use it under the guidance of a medical professional.

Side Effects:
Some reported side effects of Masitinib include nausea, vomiting, diarrhea, and abdominal pain. It's crucial for patients to report any unusual symptoms to their healthcare provider.

Dosing Information:
The dosing of Masitinib varies based on the condition being treated. It's essential to follow the prescribed dose and not to alter or skip doses without consulting a healthcare provider.

Contraindication:
Masitinib should not be used by individuals allergic to any of its components. Additionally, it may not be suitable for those with certain medical conditions or those taking specific medications. A thorough medical history and consultation are necessary before starting the drug.

Conclusion:
Masitinib is a promising drug with potential applications in various therapeutic areas. Its unique mechanism of action sets it apart from other drugs in its category. While it offers several health benefits, it's essential to be aware of its side effects and contraindications. As with any medication, it's crucial to use Masitinib under the guidance of a medical professional.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code